# 2025-08146: FDA Approves CMV Test for Baby Virus Hunt

2025-08146, Medical Devices; Immunology and Microbiology Devices; Classification of the Cytomegalovirus Nucleic Acid Detection Device for Congenital Cytomegalovirus Infection, is a Federal Register rule from Health and Human Services Department, Food and Drug Administration published 2025-05-09, effective 2025-05-09; PRIA reads it as touching household money (as of 2026-10-16).

- Canonical: https://policyrisk.com/federal-register/2025-08146
- As of: 2026-10-16
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08146
- Title: Medical Devices; Immunology and Microbiology Devices; Classification of the Cytomegalovirus Nucleic Acid Detection Device for Congenital Cytomegalovirus Infection
- Type: Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 19634
- Published: 2025-05-09
- Effective: 2025-05-09
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-16

## In one line

FDA Approves CMV Test for Baby Virus Hunt

## Summary

The FDA is officially classifying a special test that detects cytomegalovirus (CMV) in newborns as a Class II device, meaning it has special safety rules but is easier to get to patients. This change helps make sure the test is safe and effective while speeding up access to this important tool for babies and families. The new rules took effect on May 9, 2025, and could lower costs and delays for companies making these tests.

## Abstract

The Food and Drug Administration (FDA, Agency, or we) is classifying the cytomegalovirus nucleic acid detection device for congenital cytomegalovirus infection into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for the cytomegalovirus nucleic acid detection device for congenital cytomegalovirus infection's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

## Effects PRIA read

- Newborn CMV Test Moved to Class II: benefit, medium. The FDA classified the cytomegalovirus (CMV) nucleic acid detection device for diagnosing congenital CMV in newborns as Class II (special controls). The order is effective May 9, 2025, and the classification was applicable on November 30, 2018. FDA says this classification provides reasonable assur…
- Breastfeeding Timing Requirement for Samples: benefit, low. Labeling must include a statement that breast milk can cause false positive saliva results if samples are collected less than 1 hour after breastfeeding. The labeling must recommend collecting samples a minimum of 1 hour after breastfeeding.
- Test Result Interpretation Warnings: benefit, low. Labeling must state that negative CMV test results do not rule out infection and should not be the sole basis for diagnosis or treatment, and that positive results should be interpreted with other clinical and laboratory information.
- Easier Market Path for Test Makers: benefit, medium. By classifying this device as Class II via the De Novo process, FDA says the device can serve as a predicate for future devices and that this classification will reduce regulatory burdens and may lower costs and delays for companies making these tests.
- Detailed Clinical and Design Study Requirements: cost, medium. The special controls require device sponsors to provide detailed design verification and validation, analytical studies (limit of detection, inclusivity, cross-reactivity, stability), and clinical study documentation that demonstrates sensitivity and specificity. Clinical study subjects must be con…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08146 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/09/2025-08146/medical-devices-immunology-and-microbiology-devices-classification-of-the-cytomegalovirus-nucleic)
- [2025-08146 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-09/pdf/2025-08146.pdf)

## Related
- [Previous: 2025-08145, Medical Devices; Immunology and Microbiology Devices; Classification of the Mic…](https://policyrisk.com/federal-register/2025-08145)
- [Next: 2025-08147, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classifica…](https://policyrisk.com/federal-register/2025-08147)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08146 (as of 2026-10-16).
